目的 探讨健脾生血片联合罗沙司他治疗慢性肾病非透析患者肾性贫血的临床疗效。方法 选取2020年11月-2022年11月河南宏力医院接收治疗的130例慢性肾脏病3~5期非透析肾性贫血患者,随机法分对照组(65例)和治疗组(65例)。对照组患者口服罗沙司他胶囊,70 mg/次(40~60 kg),100 mg/次(≥ 60 kg),3次/周。在对照组治疗基础上,治疗组口服健脾生血片,3片/次,3次/d。两组用药12周。观察两组患者临床疗效,比较治疗前后两组患者症状缓解时间,红细胞(RBC)、红细胞比值(HT)、血红蛋白(Hb)、血清铁蛋白(SF)、白细胞介素-6(IL-6)、超氧化物歧化酶(SOD)、铁调素(Hepc)和C反应蛋白(CRP)水平,及不良反应情况。结果 治疗后,治疗组临床总有效率为98.46%,明显高于对照组总有效率(84.62%,P<0.05)。治疗后,治疗组症状缓解时间均明显早于对照组(P<0.05)。治疗后,两组患者RBC、HT、Hb、SF和SOD指标水平明显升高,而IL-6、Hepc、CRP水平明显降低(P<0.05),且治疗组这些指标水平明显好于对照组(P<0.05)。治疗后,治疗组不良反应发生率为7.69%,明显低于对照组(12.31%,P<0.05)。结论 罗沙司他联合健脾生血片治疗肾性贫血效果确切,有效改善贫血症状,降低炎性因子水平。

Objective To observe the clinical effect of Jianpi Shengxue Tablets combined with roxadustat in treatment of renal anemia in non-dialysis patients with chronic nephropathy. Methods Patients (130 cases) with non-dialytic renal anemia in stage 3-5 of chronic kidney disease in Henan Hongli Hospital from November 2020 to November 2022 were randomly divided into control (65 cases) and treatment (65 cases) group. Patients in the control group were po administered with Roxadustat Capsules, 70 mg/time (40-60 kg), 100 mg/time (≥ 60 kg), three times a week. Patients in the treatment group were po administered with Jianpi Shengxue Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the relief time of symptom, the levels of RBC, HT, Hb, SF, IL-6, Hepc, CRP and SOD, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.46%, which was significantly higher than that of the control group (84.62%, P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of RBC, HT, Hb, SF and SOD were significantly increased, while the levels of IL-6, Hepc and CRP were significantly decreased in two groups (P < 0.05), and the level of these indexes in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 7.69%, which was significantly lower than that in the control group (12.31%, P < 0.05). Conclusion Rosalastar combined with Jianpi Shengxue Tablets is effective in treatment of renal anemia, which can effectively improve the symptoms of anemia and reduce the level of inflammatory factors.

R973